TRACON Pharmaceuticals Announces Dosing Of First Patient In Phase I/II Trial Of YH001 In Combination With Envafolimab And Doxorubicin In Front Line Sarcoma

TRACON Pharmaceuticals, Inc. announced the dosing of the first patient in a Phase I/II trial evaluating the Company’s CTLA-4 antibody, YH001, in combination with its PD-L1 antibody envafolimab and with doxorubicin in front line therapy in patients with sarcoma.